Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 04, 2021 16:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition

The four winning lesson plans are now available on sharemylesson.com Lesson plans showcase creative ways to build awareness of rare disease and to build diversity and inclusion in the classroom ...
January 29, 2021 20:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 29, 2021...
January 13, 2021 08:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics

-- Alliance will assess the use of Sarepta’s proprietary gene editing technology and Genevant’s proprietary LNP delivery platform for multiple neuromuscular targets -- -- Sarepta to have options for...
January 08, 2021 08:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
January 07, 2021 16:05 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

-- Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo -- --...
December 31, 2020 18:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2020...
December 14, 2020 08:30 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Executive Management Changes

-- Ian Estepan named chief financial officer-- Dallan Murray named chief commercial officer-- Louise Rodino-Klapac, Ph.D., named chief scientific officer-- Ty Howton, general counsel, to retire from...
December 07, 2020 08:55 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

-- Results from the multiple-ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation -- -- At a total dose exposure approximately 10x lower than...
December 04, 2020 16:05 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Dec. 7, 2020...
November 30, 2020 18:05 ET | Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2020...